TESI DOTTORATO MICAELA RANIERI - DSpace - Tor Vergata

82. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH,
Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ A short term study of
chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's
disease. N Engl J Med 1997; 337: 1029-35
83. Rutgeerts P, D’Haens G, Targan S, Vasilauskas E, Hanauer SB, Present
DH, Mayer L, Van Hogezand RA, Braakman T, De Woody KL, Schaible TF,
Van Deventer SJ. Efficacy and safety of retreatment with anti tumor necrosis
factor antibody (infliximab) to mantain remission in Crohn’s disease.
Gastroenterology 1999; 117: 761-769
84. Rutgeerts P, Colombel J, Schreiber S, Mayer L, Lichtenstein G,
Rachmilewicz D, Wolf D, Malchow H, Safdi M, Feagan B, Olson A, Hanauer
S. Treatment of Crohn’s disease: response to Remicade (infliximab) in the
Accent I trial through week 54. Am J Gastroenterol 2001; 96: S303
85. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand
RA, Podolsky DK et al. Infliximab for the treatment of fistulas in patients with
with Crohn’s disease. N Engl J Med 1999; 340:1398-405
86. Baert FJ, D'Haens R, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes
K, Rutgeerts PJ TNF-α antibody (Infliximab) therapy profoundly downregulates
the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116:
22-28
87. Hanauer S, Rutgeerts P, Targan S, Kam L, Present D, Mayer L et al.
Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year
interval without treatment. Gastroenterology 1999; 116: A731
88. Bickston SJ, Lichtenstein GR, Arsenau KO, Cohen RB, Compinelli F The
relationship between infliximab treatment and limphoma in Crohn's disease.
Gastroenterology 1999; 117: 1433-1437
89. Sachmechian A, Vasiliauskas E, Abreu M, Binder S, Papadakis K,
Schaible T, Targan S, Kam L Malignancy following Remicade therapy:
incidence and characteristics. Gastroenterology 2001; 120; A-619.
90. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J,
Schwieterman WD et al. Tubercolosis associated with infliximab, a tumor
necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
91. Wrris A, Bjorneklett A, Gaustad P Invasive pulmonary aspergillosis
associated with infliximab therapy. N Engl J Med 2001; 344: 1099-1100.
92. American Thoracic Society. Targeted tubercolin testing and treatment of
latent tubercolosis infection. Am J Respir Crit Care Med 2000; 161: S221-
S247.
81